此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

中度至重度类风湿性关节炎的迷走神经刺激 (RESET-RA)

2026年11月13日 更新者:SetPoint Medical Corporation

使用 SetPoint 系统刺激中度至重度类风湿性关节炎的迷走神经:RESET-RA 研究

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.

研究概览

详细说明

The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter pivotal study enrolling up to 250 subjects at up to 45 study centers across the U.S. The study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA) who have had an inadequate response, loss of response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). The implant delivers a small amount of electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under general anesthesia. Half of the subjects will receive active stimulation (the treatment group) and the other half will receive non-active stimulation (the control group). Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety. Blinding will be maintained until the last enrolled and randomized subject in Stage 2 completes Week 12 assessments, and the study database is locked.

研究类型

介入性

注册 (实际的)

243

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Mesa、Arizona、美国、85210
        • Arizona Arthritis ans Rheumatology Research, PPLC
      • Phoenix、Arizona、美国、85037
        • Arizona Arthritis Rheumatology & Research, PLLC
      • Tucson、Arizona、美国、85704
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Covina、California、美国、91722
        • Medvin Clinical Research
      • Upland、California、美国、91786
        • Inland Rheumatology Clinical Trials
      • Whittier、California、美国、90602
        • Medvin Clinical Research
    • Colorado
      • Fort Collins、Colorado、美国、80528
        • The Arthritis & Rheumatology Clinic of Northern Colorado
    • Connecticut
      • Stamford、Connecticut、美国、06905
        • Stamford Therapeutics Consortium
    • Delaware
      • Lewes、Delaware、美国、19958
        • Delaware Arthritis
    • Florida
      • Aventura、Florida、美国、33180
        • Arthritis & Rheumatic Disease Specialties
      • Avon Park、Florida、美国、33825
        • HARAC Research Corporation
      • Boynton Beach、Florida、美国、33472
        • RecioMed Clinical Research Network, Inc.
      • Clearwater、Florida、美国、33765
        • Bay Area Rheumatology
      • Plantation、Florida、美国、33324
        • IRIS Research and Development
    • Georgia
      • Augusta、Georgia、美国、30912
        • Augusta University
      • Lawrenceville、Georgia、美国、30044
        • Parris and Associates Rheumatology
    • Illinois
      • Chicago、Illinois、美国、60611
        • Northwestern University
      • Willowbrook、Illinois、美国、60527
        • Willow Rheumatology and Wellness PLLC
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology
    • Michigan
      • Lansing、Michigan、美国、48910
        • June DO, PC
    • Minnesota
      • Eagan、Minnesota、美国、55121
        • Saint Paul Rheumatology, P.A.
    • Missouri
      • Kansas City、Missouri、美国、64151
        • Kansas City Physician Partners
      • St Louis、Missouri、美国、63122
        • West County Rheumatology
    • Nebraska
      • Lincoln、Nebraska、美国、68516
        • Physician Research Collaboration, LLC
    • New Mexico
      • Albuquerque、New Mexico、美国、87102
        • Albuquerque Center for Rheumatology
    • New York
      • Babylon、New York、美国、11702
        • Long Island Regional Arthritis & Osteoporosis Care
    • North Carolina
      • Charleston、North Carolina、美国、28202
        • Arthritis & Osteoporosis Consultants Of The Carolinas
      • Charlotte、North Carolina、美国、28210
        • DJL Clinical Research
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73103
        • Health Research of Oklahoma, PLLC
      • Oklahoma City、Oklahoma、美国、73116
        • Rheumatology Associates of Oklahoma
    • Pennsylvania
      • Allentown、Pennsylvania、美国、18103
        • Lehigh Valley Health Network
      • Philadelphia、Pennsylvania、美国、19104
        • University of Pennsylvania Medical Center
    • Texas
      • Allen、Texas、美国、75013
        • Arthritis & Rheumatology Research Institute, PLLC
      • Austin、Texas、美国、78745
        • Tekton Research
      • Austin、Texas、美国、78717
        • Austin Regional Clinic
      • Austin、Texas、美国、78746
        • Central Texas Rheumatology Associates
      • Colleyville、Texas、美国、76034
        • Precision Comprehensive Clinical Research Solutions
      • Houston、Texas、美国、77043
        • Biopharma Informatic
      • Mesquite、Texas、美国、75150
        • Southwest Rheumatology Research LLC
      • San Antonio、Texas、美国、78229
        • Clinical Trials of Texas, Inc
    • Virginia
      • Fairfax、Virginia、美国、22033
        • Annapolis Rheumatology
    • Washington
      • Bothell、Washington、美国、98021
        • Sound Clinical Research, LLC
    • West Virginia
      • Morgantown、West Virginia、美国、26506
        • West Virginia University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

22年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • 22-75 years of age at screening
  • Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
  • Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
  • Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12

Exclusion Criteria:

  • Untreated or poorly controlled psychiatric illness or history of substance abuse
  • Significant immunodeficiency due to underlying illness
  • History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
  • Clinically significant cardiovascular disease
  • Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
  • Uncontrolled fibromyalgia
  • History of left or right carotid surgery
  • History of unilateral or bilateral vagotomy, partial or complete splenectomy
  • Recurrent vasovagal syncope episodes
  • Current, regular use of tobacco products
  • Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment

Active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

其他名称:
  • 手术将迷走神经刺激器置于颈部内

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

其他名称:
  • 常规合成 DMARD 的背景治疗

Active stimulation for 1 min once per day

假比较器:Control

Non-active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

其他名称:
  • 手术将迷走神经刺激器置于颈部内

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

其他名称:
  • 常规合成 DMARD 的背景治疗

Non-active stimulation for 1 min once per day

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
the American College of Rheumatology (ACR) 20 Response
大体时间:Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

次要结果测量

结果测量
措施说明
大体时间
DAS28-CRP Good or Moderate Response as Defined by European League Against Rheumatism (EULAR)
大体时间:Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

A subject is considered having a moderate treatment response if:

  • DAS28-CRP score improvement from baseline to Week 12 is > 0.6 and ≤ 1.2, and the DAS28-CRP score at Week 12 is ≤ 5.1; or
  • DAS28-CRP score improvement from baseline to Week 12 is > 1.2, and the DAS28-CRP score at Week 12 is > 3.2.

A subject is considered having a good treatment response if:

• DAS28-CRP score improvement from baseline to Week 12 is > 1.2 and the DAS28-CRP score at Week 12 is ≤ 3.2

Week 12
DAS28-CRP Response (MCID -1.2) at Week 12
大体时间:Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) response is based on the minimal clinically important difference (MCID) of -1.2 from baseline.

DAS28-CRP is based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

Week 12
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22)
大体时间:Week 12

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 12
ACR20 Response at Week 12 From Day 0
大体时间:Week 12

Response is defined as achieving at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL).

Week 12

其他结果措施

结果测量
措施说明
大体时间
Bone Erosion Progression, All Completers
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers With Erosive Phenotype
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers That Previously Only Failed 1 b/tsDMARD
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Change in Erosion Score, All Completers
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers With Erosive Phenotype
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers That Previously Only Failed 1 b/tsDMARD
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Synovitis Score, All Completers
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers With Erosive Phenotype
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Osteitis Score, All Completers
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers With Erosive Phenotype
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
大体时间:Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission
大体时间:Week 12

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 12
DAS28-CRP Low Disease Activity (LDA) or Remission
大体时间:Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 12
the American College of Rheumatology (ACR) 20 Response, All Completers
大体时间:Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
the American College of Rheumatology (ACR) 20 Response, Non-augmented
大体时间:Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
大体时间:Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
大体时间:Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
大体时间:Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
大体时间:Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
大体时间:Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
大体时间:Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Study Participants That Are Somewhat to Very Satisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
大体时间:Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Neither Satisfied Nor Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
大体时间:Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Somewhat to Very Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
大体时间:Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Would Recommend the SetPoint System to a Family Member or Friend
大体时间:Week 24

Patients were asked a question about whether they would recommend the SetPoint System to family and friends

Week 24
the American College of Rheumatology (ACR) 20 Response, All Completers
大体时间:Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
the American College of Rheumatology (ACR) 20 Response, Non-augmented
大体时间:Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
大体时间:Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
大体时间:Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
大体时间:Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
大体时间:Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
大体时间:Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
大体时间:Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
the American College of Rheumatology (ACR) 20 Response, All Completers
大体时间:Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
the American College of Rheumatology (ACR) 20 Response, Non-augmented
大体时间:Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
大体时间:Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
大体时间:Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
大体时间:Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
大体时间:Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
大体时间:Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
大体时间:Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
the American College of Rheumatology (ACR) 20 Response, Subjects With 1 Prior b/tsDMARD
大体时间:Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 2 Prior b/tsDMARD
大体时间:Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 3 Prior b/tsDMARD
大体时间:Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With >=4 Prior b/tsDMARD
大体时间:Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mark Richardson, MD PhD、Massachusetts General Hospital
  • 首席研究员:John Tesser, MD、Arizona Arthritis and Rheumatology Research, P.C.

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年1月11日

初级完成 (实际的)

2024年5月16日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2020年8月31日

首先提交符合 QC 标准的

2020年8月31日

首次发布 (实际的)

2020年9月7日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年1月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

No sharing data is planned.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅